Spectral Med Stock Today
| EDT Stock | CAD 0.53 0.03 6.00% |
Performance0 of 100
| Odds Of DistressOver 84
|
Spectral Med is selling at 0.53 as of the 23rd of November 2024; that is 6.00 percent increase since the beginning of the trading day. The stock's open price was 0.5. Spectral Med has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Spectral Med are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of November 2023 and ending today, the 23rd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Spectral Medical Inc. focuses on the development and commercialization of treatment for septic shock in North America. Spectral Medical Inc. was founded in 1991 and is headquartered in Toronto, Canada. SPECTRAL MEDICAL operates under Diagnostics Research classification in Canada and is traded on Toronto Stock Exchange. The company has 282.82 M outstanding shares of which 95.22 K shares are currently shorted by private and institutional investors with about 1.04 days to cover all short positions. More on Spectral Med
Moving against Spectral Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Spectral Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Spectral Med's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Spectral Med or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | ||||
Spectral Med's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Spectral Med's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsSpectral Med can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Spectral Med's financial leverage. It provides some insight into what part of Spectral Med's total assets is financed by creditors.
| |||||
Spectral Med (EDT) is traded on Toronto Exchange in Canada and employs 29 people. Spectral Med is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 149.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Spectral Med's market, we take the total number of its shares issued and multiply it by Spectral Med's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Spectral Med operates under Biotechnology sector and is part of Health Care industry. The entity has 282.82 M outstanding shares of which 95.22 K shares are currently shorted by private and institutional investors with about 1.04 days to cover all short positions.
Spectral Med has accumulated about 3.8 M in cash with (11.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check Spectral Med Probability Of Bankruptcy
Ownership AllocationSpectral Med shows a total of 282.82 Million outstanding shares. Spectral Med has 18.13 % of its outstanding shares held by insiders and 12.95 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Spectral Ownership Details
Spectral Med Risk Profiles
Although Spectral Med's alpha and beta are two of the key measurements used to evaluate Spectral Med's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.82 | |||
| Standard Deviation | 3.55 | |||
| Variance | 12.57 | |||
| Risk Adjusted Performance | (0.06) |
Spectral Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Spectral Med without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Spectral Med Corporate Management
Elected by the shareholders, the Spectral Med's board of directors comprises two types of representatives: Spectral Med inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spectral. The board's role is to monitor Spectral Med's management team and ensure that shareholders' interests are well served. Spectral Med's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spectral Med's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sam Amory | Pres Inc | Profile | |
| BSc RN | VP Devel | Profile | |
| Blair McInnis | Chief Officer | Profile | |
| Christopher Seto | CEO Director | Profile | |
| John MD | Chief Officer | Profile |
Other Information on Investing in Spectral Stock
Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.